Most are mild, short-lived, and linked to how treatment affects your appetite and digestion
The latest dual-action GLP-1 analogue, tirzepatide , which also affects GIP receptors, was approved in the US in 2022 as the drug Mounjaro for the treatment of type 2 diabetes, and in 2023 as Zepbound for the treatment of obesity and excess weight, as well as obstructive sleep apnea syndrome in obese individuals
[18] [5] Rapid weight loss associated with this class of medication may increase the risk of gallbladder disease, including gallstones
Dietary modifications: Gradually increase dietary fiber intake to 25-35 grams daily through whole grains, fruits, vegetables, and legumes Maintain adequate hydration (aim for pale yellow urine as an indicator of proper hydration) Avoid excessive caffeine and alcohol, which can contribute to dehydration Consider a fiber supplement (psyllium, methylcellulose) if dietary intake is insufficient, starting with a low dose and increasing gradually Bowel habit optimization: Respond promptly to the urge to defecate rather than delaying Avoid prolonged sitting on the toilet (limit to 5 minutes or less) Do not strain during bowel movements
One critical area of focus in our practice is the management of diabetes and weight-related conditions through innovative therapies, including treatments that target the hormone GLP-1
Step 2: Virtual Clinical Consultation A licensed clinician reviews your information and determines whether GLP-1 therapy is medically appropriate for you
